Rachna Shroff, MD, MS, University of Arizona College of Medicine, Tucson, AZ, discusses the latest developments in the targeted therapies for biliary tract cancers, including encouraging findings from the ReFocus trial (NCT04526106) of RLY-4008, an FGFR2 inhibitor, in patients with cholangiocarcinoma. Additional treatment options include ivosidenib and zanidatamab for patients with IDH-1 and HER-2 mutated cholangiocarcinoma respectively. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.